MedTrace Logo

Comparison of Postoperative Effects of Articaine and Lidocaine in Mucogingival Surgery

NCT07145879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-08-28

No results posted yet for this study

Summary

The aim of this study is to compare and evaluate the effects of using lidocaine 2% (with adrenaline) and articaine 4% (with adrenaline) in free gingival graft (FGG) surgery on postoperative wound healing, changes in blood flow in the surgical area during the healing process, patients' postoperative pain levels, and anxiety levels before and after surgery.

Conditions

  • Local Analgesia Via Infiltration
  • Wound Heal
  • Pain, Postoperative
  • Hemorrhage

Interventions

DRUG

Lidocaine hydrochloride 2% with epinephrine 1:100 000

Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL) and 0.012 mg epinephrine base. Excipients: Sodium metabisulfite, sodium chloride, water for injection.

DRUG

Articaine 4% with epinephrine 1:100,000

Patients were received Infiltrative anesthesia with Articaine (Ultracain DS Forte, Sanofi Aventis İlaçları, Istanbul, Türkiye): Active ingredient: 40 mg articaine HCL and 0.012 mg epinephrine per 1 ml. Excipients: Sodium chloride, sodium metabisulfite, hydrochloric acid, water for injection

PROCEDURE

Free gingival graft (FGG)

FGG surgery was performed around natural teeth and implants where keratinized gingival tissue was inadequate.

Sponsors & Collaborators

  • Pamukkale University

    lead OTHER

Principal Investigators

  • Aysan Lektemur Alpan, PhD DDS · Pamukkale University Faculty of Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-07-30
Completion
2025-07-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145879 on ClinicalTrials.gov